Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial

Next Previous
Trial Profile

Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levamisole (Primary)
  • Indications Nephrotic syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Ace Pharmaceuticals

    • Most Recent Events

    • 19 Dec 2013 According to an Ace Pharmaceuticals media release, Professor Jean Claude Davin and pediatrician Mariken Gruppen of the AMC (Academic Medical Center, Amsterdam) were acting as principal investigator (JCD) and study coordinator.
    • 19 Dec 2013 According to an Ace Pharmaceuticals media release, database lock date of this study was 19th December 2013.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top